Pediatrics. Consilium MedicumPediatrics. Consilium Medicum2658-66302658-6622Consilium Medicum5709710.26442/26586630.2019.4.190750Research ArticleEXPERIENCE OF TREATMENT WITH GROPRINOSIN (INOSINE PRANOBEX) FOR HERPES VIRUS INFECTION IN CHILDREN WITH EPILEPSY AND INFANTILE CEREBRAL PALSYSavenkovaMarina S.mpsavenkov@mail.ruBalakirevaGalina M.-KuznetsovaElena S.-RumiantsevaIrina G.-Afanas'evaAida A.-SavenkovaAnna M.-OsipovaKarina V.-KarazhasNatalia V.-RybalkinaTatiana N.-LysenkovaMariia lu.-DushkinRoman V.-Pirogov Russian National Research Medical UniversityVoino-Yasenetski Scientific and Practical Center for Specialized Medical Care for ChildrenGamaleya National Research Centre for Epidemiology and MicrobiologyArtificial Intelligence Agency151220194515729122020Copyright © 2019, Consilium Medicum2019Relevance. Previous studies showed an important role of herpes viruses in children with epilepsy and infantile cerebral palsy (ICP). Materials and methods. This study was conducted from 2014 to 2018 on the basis of the Voino-Yasenetski Scientific and Practical Center for Specialized Medical Care for Children and the Morozov Children's City Clinical Hospital. Serological and microbiological molecular genetic (PCR test) methods, ELISA test, indirect immunofluorescence reaction and rapid culture method were used to confirm herpes infection. In the open prospective study 298 children with epilepsy and ICP were included, in 131 (44%) of them herpes infection was revealed. 100 children who received inosine pranobex (Groprinosin®) were under follow-up: 92 children were in the hospital and 8 children were outpatient. Inclusion criteria were: children aged 3-15 years with epilepsy and ICP. Most children have symptomatic focal epilepsy. Exclusion criteria were: age less than 3 years, severe hematological, oncological and somatic diseases. Children were divided into the following groups: group 1 - epilepsy (n=36); group 2 - epilepsy + ICP (n=20); group 3 - ICP (n=44). The comparison group (group 4) included 31 children aged 3 to 15 years with herpes virus infections: epilepsy (n=25) and cerebral palsy (n=6), who took conventional anticonvulsant therapy without inosine pranobex. Results. In the group of children examined, mainly aged 3-6 years, the most prevalent infections were cytomegalovirus (75.3%) and human herpes virus (HHV)-6 (86.2%) along with Epstein-Barr virus and HHV-1, HHV-2. Patients infected with cytomegalovirus and HHV-6 have mainly an acute course of disease (40.9 and 51.9%, respectively) while patient with Epstein-Barr virus and HHV-1, HHV-2 have a persistent chronic course of disease (76.1 and 75.5%, respectively). Most of the examined children showed mixed infection with 2 or 3 different herpes viruses. In groups of children who took inosine pranobex, treatment showed highly beneficial effect on dynamics of clinical, laboratory and instrumental parameters.epilepsyinfantile cerebral palsyherpes infectionsinosine pranobexGroprinosinэпилепсиядетский церебральный параличгерпетические инфекцииинозин пранобексГроприносин[Мухин К.Ю. Определение и классификация эпилепсии. Проект классификации эпилептических приступов 2016 года. Рус. журн. детской неврологии. 2017; 12 (12): 8-20. @@Mukhin K.Iu. Opredelenie i klassifikatsiia epilepsii. Proekt klassifikatsii epileptic-heskikh pristupov 2016 goda. Rus. zhurn. detskoi nevrologii. 2017; 12 (12): 8-20 (in Russian).][Fisher RS, Acevedo C, Arzimanoglou A et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55 (4): 475-82.][Белоусова ЕД., Заваденко Н.Н., Холин А.А., Шарков А.А. Новые международные классификации эпилепсий и эпилептических приступов Международной лиги по борьбе с эпилепсией (2017). Журн. неврологии и психиатрии им. С.С. Корсакова. 2017; 7: 99-106.][Воронкова К.В., Пылаева О.А., Косякова Е.С. и др. Современные принципы терапии эпилепсии. Журн. неврологии и психиатрии им. С.С. Корсакова. 2010; 6. @@Voronkova K.V., Pylaeva O.A., Kosiakova E.S. et al. Sovremennye printsipy terapii epilepsii. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2010; 6 (in Russian).][Вашура Л.В., Савенкова М.С., Заваденко Н.Н. и др. Судорожный синдром у детей: роль герпесвирусных инфекций. Детские инфекции. 2014; 2: 48-52. @@Vashura L.V., Savenkova M.S., Zavadenko N.N. et al. Sudorozhnyi sindrom u detei: rol' gerpesvirusnykh infektsii. Detskie infektsii. 2014; 2: 48-52 (in Russian).][Вашура Л.В., Савенкова М.С. Герпес 6 типа (эпидемиология, диагностика, клиника). Лечащий врач. 2014; 11: 18-24. @@Vashura L.V., Savenkova M.S. Gerpes 6 tipa (epidemiologiia, diagnostika, klinika). Lechashchii vrach. 2014; 11: 18-24 (in Russian).][Симонова Е.В., Харламова Ф.С., Учайкин В.Ф. и др. Поражение ЦНС при моно-и микст-инфекции герпеса человека 6-го типа. Педиатрия. 2016; 95 (2): 22-9. @@Simonova E.V., Kharlamova F.S., Uchaikin V.F et al. Porazhenie TsNS pri mono- i mikst-infektsii gerpesa cheloveka 6-go tipa. Pediatriia. 2016; 95 (2): 22-9 (in Russian).][Epstein LG, Shinnar S, Hesdorffer DC et al. Shumei Sun and the FEBSTAT study team. Epilepsia;Ybman herpesvirus 6 and 7 in febrile status epilepticus: The FEBSTAT study. Published Online: june 14, 2012.][Латышева Т.В., Павлова К.С. Сравнительная оценка эффективности Гроприно-сина и общепринятой терапии у пациентов, часто и длительно болеющих респираторными вирусными заболеваниями. Клин. фармакология и терапия. 2016; 26 (4): 36-40. @@Latysheva TV, Pavlova K.S. Sravnitel'naia otsenka effektivnosti Groprinosina i obshche-priniatoi terapii u patsientov, chasto i dlitel'no boleiushchikh respiratornymi virusnymi zabolevaniiami. Klin. farmakologiia i terapiia. 2016; 26 (4): 36-40 (in Russian).][Сергиенко Е.Н. Применение Гроприносина в педиатрической практике: обзор литературы. Мед. новости. 2016; 9: 37-40. @@Sergienko E.N. Primenenie Groprinosina v pediatricheskoi praktike: obzor litera-tury Med. novosti. 2016; 9: 37-40 (in Russian).][Савенкова М.С., Афанасьева А.А., Балакирева Г.М. и др. Клинический опыт лечения заболеваний дыхательных путей препаратом Гроприносин (инозин пра-нобекс) в педиатрической практике. Педиатрия (Прил. к журн. Consilium Medicum). 2018; 4: 32-6.][Руженцова Т.А., Плоскирева АА., Алешина Н.И. и др. Возможности повышения эффективности терапии острых респираторных вирусных инфекций различной этиологии у детей. Инфекционные болезни. 2019; 17: 46-52. @@Ruzhentsova TA., Ploskireva A.A., Aleshina N.I. et al. Vozmozhnosti povysheniia ef-fektivnosti terapii ostrykh respiratornykh virusnykh infektsii razlichnoi etiologii u detei. Infektsionnye bolezni. 2019; 17: 46-52 (in Russian).][Harper DR. Viruses: biology, applications, and control. 2012; p. 324.]